LABORATORIO FARMAC.ERFO (RK7) — Capital Reinvestment Ratio

Latest as of December 2023: 1.11x

LABORATORIO FARMAC.ERFO (RK7) has a Capital Reinvestment Ratio of 1.11x as of December 2023, meaning it reinvests 1% of its operating cash flow (€1.30 Million) in capital expenditures (€1.45 Million). Check RK7 tangible net worth ratio to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

1.11x
Capex / Operating Cash Flow

Operating Cash Flow

€1.30 Million
EUR

Capital Expenditures

€1.45 Million
EUR

Data as of

Dec 2023
Most recent filing

LABORATORIO FARMAC.ERFO Capital Reinvestment Ratio (2021–2023)

This chart tracks LABORATORIO FARMAC.ERFO's Capital Reinvestment Ratio across 3 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of LABORATORIO FARMAC.ERFO.

Annual Capital Reinvestment Ratio for LABORATORIO FARMAC.ERFO (2021–2023)

Year-by-year Capital Reinvestment Ratio for LABORATORIO FARMAC.ERFO from 2021 to 2023. See LABORATORIO FARMAC.ERFO (RK7) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (EUR) Capital Expenditures YoY Change
2023 1.11x €1.30 Million €1.45 Million ▼ -27.9%
2022 1.55x €761.80K €1.18 Million ▲ +1347.6%
2021 0.11x €2.27 Million €242.84K
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow